Sekar Kathiresan Form 3 Verve Therapeutics / Sekar Kathiresan ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Kathiresan Sekar

(Last) (First) (Middle)

C/O VERVE THERAPEUTICS, INC.

500 TECHNOLOGY SQUARE, SUITE 901

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/16/2021

3. Issuer Name and Ticker or Trading Symbol
Verve Therapeutics, Inc. [ VERV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
Chief Executive Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	404,036	D
Common Stock	80,997	I	Kathiresan Family 2021 Irrevocable Trust
Common Stock	80,997	I	Sekar Kathiresan 2021 Irrevocable Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	02/11/2031	Common Stock	431,988	8.24	D
Stock Option (right to buy)	(2)	09/15/2030	Common Stock	674,982	2.87	D
Stock Option (right to buy)	(3)	04/14/2029	Common Stock	188,995	1.39	D
Stock Option (right to buy)	(4)	04/14/2029	Common Stock	431,988	1.39	D

Explanation of Responses:

1. The option was granted on February 12, 2021 for 431,988 shares. 25% of the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025.

2. The option was granted on September 16, 2020 for 674,982 shares. 25% of the shares underlying the option will vest on September 16, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until September 16, 2024.

3. The option was granted on April 15, 2019 for 188,995 shares. 25% of the shares underlying the option vested on March 25, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until March 25, 2024.

4. The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments thereafter until July 22, 2023.

Remarks:

Exhibit Index: 24.1 Power of Attorney

	/s/ Andrew Ashe, Attorney-in-Fact	06/16/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.